RCM
GBT

Riverhead Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Riverhead Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$7K Hold
149
– – ﹤0.01% 1497
2019
Q2 		$8K Buy
149
+10
+7% +$575 ﹤0.01% 1515
2019
Q1 		$7K Sell
139
-239
-63% -$11.7K ﹤0.01% 1489
2018
Q4 		$16K Buy
+378
New +$14.2K ﹤0.01% 1473

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Riverhead Capital Management's GBT Position: Q3 2019 in Review

Riverhead Capital Management held its Global Blood Therapeutics, Inc. (GBT) position steady in Q3 2019 at 149 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #1497.

Riverhead Capital Management first reported a position in GBT in Q4 2018 and has held it in 4 quarters since. The position peaked at $16K in Q4 2018. 208 funds tracked by Wall St. Rank hold GBT as of Q3 2019.

  • Riverhead Capital Management held 149 shares of Global Blood Therapeutics, Inc. worth $7K as of Q3 2019.
  • Riverhead Capital Management left its Global Blood Therapeutics, Inc. share count unchanged in Q3 2019.
  • Global Blood Therapeutics, Inc. made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1497 holding.
  • Riverhead Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2018 and has held it in 4 quarters since.
  • Riverhead Capital Management's Global Blood Therapeutics, Inc. position peaked at $16K in Q4 2018.
  • 208 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.